Fox Run Management L.L.C. Increases Stake in LivaNova PLC $LIVN

Key Points

• Fox Run Management L.L.C. increased its stake in LivaNova PLC by 35.3%, acquiring 6,995 shares valued at approximately $1,054,000.
• LivaNova reported earnings of $1.05 per share, surpassing analysts' expectations, with a year-over-year revenue growth of 10.6% to $352.50 million.
• Stocks of LivaNova have been positively rated by various analysts, with a consensus rating of "Buy" and an average target price of $59.29.

Fox Run Management L.L.C. grew its holdings in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 35.3% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 26,838 shares of the company's stock after purchasing an additional 6,995 shares during the period. Fox Run Management L.L.C.'s holdings in LivaNova were worth $1,054,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the business. Nuveen LLC acquired a new position in LivaNova during the first quarter worth $30,954,000. Freestone Grove Partners LP purchased a new stake in shares of LivaNova during the 4th quarter worth $23,102,000. The Manufacturers Life Insurance Company grew its stake in shares of LivaNova by 163.6% during the 4th quarter. The Manufacturers Life Insurance Company now owns 546,387 shares of the company's stock worth $25,303,000 after purchasing an additional 339,139 shares during the period. AQR Capital Management LLC grew its stake in shares of LivaNova by 79.3% during the 4th quarter. AQR Capital Management LLC now owns 742,180 shares of the company's stock worth $34,214,000 after purchasing an additional 328,313 shares during the period. Finally, LSV Asset Management increased its holdings in shares of LivaNova by 278.3% in the 1st quarter. LSV Asset Management now owns 438,498 shares of the company's stock valued at $17,224,000 after purchasing an additional 322,598 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms recently commented on LIVN. Needham & Company LLC reissued a "buy" rating and set a $64.00 price objective on shares of LivaNova in a report on Tuesday, May 13th. Wolfe Research upgraded shares of LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 price target for the company in a research report on Tuesday, May 20th. Wall Street Zen raised LivaNova from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 9th. Robert W. Baird upped their price target on LivaNova from $55.00 to $61.00 and gave the stock an "outperform" rating in a report on Thursday, May 8th. Finally, Barclays reduced their price objective on LivaNova from $56.00 to $55.00 and set an "equal weight" rating for the company in a report on Thursday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $59.29.

LivaNova Price Performance

LIVN stock traded down $0.09 during trading on Wednesday, hitting $53.39. The stock had a trading volume of 561,501 shares, compared to its average volume of 833,326. The stock has a market cap of $2.92 billion, a price-to-earnings ratio of -13.72 and a beta of 0.92. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.09 and a current ratio of 1.29. The company's 50 day moving average price is $46.09 and its two-hundred day moving average price is $42.98. LivaNova PLC has a 1-year low of $32.48 and a 1-year high of $57.35.

LivaNova (NASDAQ:LIVN - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported $1.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.84 by $0.21. The company had revenue of $352.50 million for the quarter, compared to analysts' expectations of $332.20 million. LivaNova had a negative net margin of 16.13% and a positive return on equity of 14.57%. The firm's revenue for the quarter was up 10.6% compared to the same quarter last year. During the same period last year, the company earned $0.93 EPS. On average, sell-side analysts forecast that LivaNova PLC will post 2.85 EPS for the current fiscal year.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.